Evidence map›Paper›PMID 36812307›Full record

ArticleScience advances2023

PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells.

Kristina Ames, Imit Kaur, Yang Shi, Meng M Tong, Taneisha Sinclair, Shayda Hemmati, Shira G Glushakow-Smith, Ellen Tein, Lindsay Gurska, Ulrich Steidl and 6 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Kristina AmesDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-6845-0898
Imit KaurDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Yang ShiDepartment of Pathology, Montefiore Hospital, Bronx, NY, USA.ORCID 0000-0003-2168-5590
Meng M TongDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Taneisha SinclairDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Shayda HemmatiDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Shira G Glushakow-SmithDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-6012-7236
Ellen TeinDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-5081-6599
Lindsay GurskaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Ulrich SteidlDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-9458-1795
Robert DubinDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.
Jidong ShanDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.
Cristina MontagnaDepartment of Radiation Oncology and Genomic Instability and Cancer Genetics, Rutgers Cancer Institute of New Jersey, NJ, USA.ORCID 0000-0003-2343-5851
Kith PradhanDepartment of Medical Oncology, Montefiore Hospital, Bronx, NY, USA.
Amit VermaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-5408-1673
Kira GritsmanDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-1367-1167
Albert Einstein College of Medicine · USMontefiore Medical Center · USCancer Genetics (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2M
TRAINING PROGRAM IN CELLULAR &MOLEC. BIOLOGY &GENETICST32GM007491 · NIGMS · YESHIVA UNIVERSITY · PI QUERY, CHARLES C · 1985 to 2021
$17.0M
Bronx-Einstein Training in Teaching and Research (BETTR), an IRACDA programK12GM102779 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Dianne Cox, Johanna Patricia Daily · 2012 to 2026
$9.2M
PI3 Kinase Inactivation in Myelodysplastic SyndromeR01DK130895 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GRITSMAN, KIRA · 2022 to 2025
$2.2M
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid LeukemiaR01CA196973 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GRITSMAN, KIRA · 2016 to 2020
$2.0M
The p110 alpha and delta isoforms of PI3 kinase in hematopoiesis and leukemiaK08CA149208 · NCI · DANA-FARBER CANCER INST · PI GRITSMAN, KIRA · 2010 to 2014
$889k
Advanced Confocal Microscope in a multi-user facilityS10OD023591 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BAKER, NICHOLAS E · 2017 to 2017
$590k
Cytek Aurora Multiparameter Flow CytometerS10OD026833 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PORCELLI, STEVEN A · 2019 to 2019
$367k
Role of the Class IA PI3K in Hematopoietic Stem Cell Self-RenewalF32HL146119 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AMES, KRISTINA · 2019 to 2022
$213k
RON kinase as a novel therapeutic target in myeloproliferative neoplasmsF31CA247172 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GURSKA, LINDSAY · 2020 to 2022
$113k
PI3 Kinase Inactivation in Myelodysplastic SyndromeR56DK130895 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GRITSMAN, KIRA · 2021 to 2021
$100k
NCI NIH HHS F31 CA247172NCI NIH HHS K08 CA149208NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA196973NHLBI NIH HHS F32 HL146119NIDDK NIH HHS R01 DK130895NIDDK NIH HHS R56 DK130895NIGMS NIH HHS K12 GM102779NIGMS NIH HHS T32 GM007491NIH HHS S10 OD023591NIH HHS S10 OD026833
6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a clonal malignancy arising in hematopoietic stem cells (HSCs). The mechanisms of MDS initiation in HSCs are still poorly understood. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is frequently activated in acute myeloid leukemia, but in MDS, PI3K/AKT is often down-regulated. To determine whether PI3K down-regulation can perturb HSC function, we generated a triple knockout (TKO) mouse model with

Indexed as

Myelodysplastic SyndromesPhosphatidylinositol 3-KinasesAnimalsCell DifferentiationHematopoietic Stem CellsMiceMice, KnockoutProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID36812307
PMCPMC9946350
OpenAlexW4321481089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.